$2.91
2.46% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US2307701092
Symbol
CPIX

Cumberland Pharmaceuticals Inc. Stock price

$2.91
-0.49 14.41% 1M
-2.29 44.04% 6M
+0.54 22.78% YTD
+1.49 104.93% 1Y
+0.46 18.78% 3Y
-0.57 16.38% 5Y
-3.11 51.66% 10Y
-13.92 82.71% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.07 2.46%
ISIN
US2307701092
Symbol
CPIX
Industry

Key metrics

Basic
Market capitalization
$42.5m
Enterprise Value
$31.6m
Net debt
positive
Cash
$16.1m
Shares outstanding
15.0m
Valuation (TTM | estimate)
P/E
negative | -
P/S
1.0 | -
EV/Sales
0.8 | -
EV/FCF
4.6
P/B
1.5
Financial Health
Equity Ratio
30.2%
Return on Equity
-28.4%
ROCE
-6.8%
ROIC
-10.5%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$42.1m | -
EBITDA
$1.6m | -
EBIT
$-3.0m | -
Net Income
$-2.9m | -
Free Cash Flow
$6.9m
Growth (TTM | estimate)
Revenue
11.3% | -
EBITDA
124.5% | -
EBIT
72.7% | -
Net Income
71.8% | -
Free Cash Flow
794.0%
Margin (TTM | estimate)
Gross
84.0%
EBITDA
3.7% | -
EBIT
-7.1%
Net
-7.0% | -
Free Cash Flow
16.5%
More
EPS
$-0.2
FCF per Share
$0.5
Short interest
0.1%
Employees
91
Rev per Employee
$420.0k
Show more

Is Cumberland Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cumberland Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cumberland Pharmaceuticals Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Cumberland Pharmaceuticals Inc. forecast:

Hold
50%
Sell
50%

Financial data from Cumberland Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
42 42
11% 11%
100%
- Direct Costs 6.74 6.74
2% 2%
16%
35 35
13% 13%
84%
- Selling and Administrative Expenses 28 28
1% 1%
68%
- Research and Development Expense 5.36 5.36
1% 1%
13%
1.56 1.56
125% 125%
4%
- Depreciation and Amortization 4.55 4.55
1% 1%
11%
EBIT (Operating Income) EBIT -2.99 -2.99
73% 73%
-7%
Net Profit -2.93 -2.93
72% 72%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Cumberland Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cumberland Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
7 days ago
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP & CFO Todd M.
Neutral
PRNewsWire
7 days ago
NASHVILLE, Tenn. , Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period.
Neutral
PRNewsWire
8 days ago
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers NASHVILLE, Tenn. , Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced the availability of the Vibativ® (telavancin) 4-Vial Starter Pak through a new...
More Cumberland Pharmaceuticals Inc. News

Company Profile

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Head office United States
CEO A. Kazimi
Employees 91
Founded 1999
Website www.cumberlandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today